Tocilizumab treatment safety in rheumatoid arthritis in a patient with multiple sclerosis: A case report

BMC Research Notes

Volumn 7, Issue 1, 2014, Pages

  Sato, Hiroe ^a,b   Kobayashi, Daisuke ^a   Abe, Asami ^a   Ito, Satoshi ^a   Ishikawa, Hajime ^a   Nakazono, Kiyoshi ^a   Murasawa, Akira ^a   Kuroda, Takeshi ^b   Nakano, Masaaki ^c   Narita, Ichiei ^b  

^a Niigata Rheumatic Centre   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c NIIGATA UNIVERSITY   (Japan)

Author keywords

Interleukin 6; Multiple sclerosis; Rheumatoid arthritis; Tocilizumab; Tumour necrosis factor

Indexed keywords

MONOCLONAL ANTIBODY; TOCILIZUMAB;

CASE REPORT; COMPLICATION; FEMALE; HUMAN; MIDDLE AGED; MULTIPLE SCLEROSIS; REMISSION; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS; REMISSION INDUCTION;

EID: 84908018550     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-7-641     Document Type: Article

References (15)

1. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. Sharief MK, Hentges R, N Engl J Med 1991 325 467 472 10.1056/NEJM199108153250704 1852181
2. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, Neurology 1999 53 457 465 10449104
3. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH, Neurology 1996 47 1531 1534 10.1212/WNL.47.6.1531 8960740
4. Rheumatoid arthritis and multiple sclerosis in the same patient. Two case-reports. Attout H, Toussirot E, Auge B, Chavot D, Wendling D, Rev Rhum Engl Ed 1999 66 169 172 10327497
5. A case of multiple sclerosis associated with rheumatoid arthritis and positive anticardiolipin antibodies. Mpofu S, Moots RJ, Ann Rheum Dis 2003 62 376 10.1136/ard.62.4.376 12634248
6. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T, Cytokine 2009 45 55 57 10.1016/j.cyto.2008.11.002 19109035
7. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Lozeron P, Denier C, Lacroix C, Adams D, Arch Neurol 2009 66 490 497 19364934
8. Neurological adverse events associated with anti-tumor necrosis factor alpha treatment. Tristano AG, J Neurol 2010 257 1421 1431 10.1007/s00415-010-5591-7 20495815
9. Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1∗0404 allele. Levesque MC, Ward FE, Jeffery DR, Weinberg JB, Arthritis Rheum 1999 42 569 573 10.1002/1529-0131(199904)42:3<569::AID-ANR23>3.0.CO;2-M 10088781
10. Beneficial effect of interferon-beta treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-beta injection. Nakatsuji Y, Nakano M, Moriya M, Kishigami H, Tatsumi C, Tada S, Sadahiro S, Naka T, Mitani K, Funauchi M, Azuma T, Watanabe S, Kinoshita M, Kajiyama K, Yuasa Y, Kaido M, Takahashi MP, Naba I, Hazama T, Sakoda S, Osaka Neurological Research Consortium, Cytokine 2006 36 69 74 10.1016/j.cyto.2006.10.013 17161613
11. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, Otsuka J, Okamura S, Fujita S, Harada M, Gastroenterology 2005 128 376 392 10.1053/j.gastro.2004.11.060 15685549
12. Tumour necrosis factor microsatellites show association with multiple sclerosis. Kirk CW, Droogan AG, Hawkins SA, McMillan SA, Nevin NC, Graham CA, J Neurol Sci 1997 147 21 25 10.1016/S0022-510X(96)00313-9 9094056
13. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). Kobayashi K, Okamoto Y, Inoue H, Usui T, Ihara M, Kawamata J, Miki Y, Mimori T, Tomimoto H, Takahashi R, Intern Med 2009 48 1307 1309 10.2169/internalmedicine.48.1926 19652436
14. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Fujimoto M, Serada S, Mihara M, Uchiyama Y, Yoshida H, Koike N, Ohsugi Y, Nishikawa T, Ripley B, Kimura A, Kishimoto T, Naka T, Arthritis Rheum 2008 58 3710 3719 10.1002/art.24126 19035481
15. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Serada S, Fujimoto M, Mihara M, Koike N, Ohsugi Y, Nomura S, Yoshida H, Nishikawa T, Terabe F, Ohkawara T, Takahashi T, Ripley B, Kimura A, Kishimoto T, Naka T, Proc Natl Acad Sci U S A 2008 105 9041 9046 10.1073/pnas.0802218105 18577591